Avenue Therapeutics, Inc. (ATXI) 10-Year Financial Performance & Capital Metrics

ATXI • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.Show more

Revenue $0
EBITDA -$12M
Net Income -$12M -12.3%
EPS (Diluted) -0.90 +98.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -928.45% -75.4%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 87 (top 13%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM123.81%

ROCE

10Y Avg-422.59%

5Y Avg-424.57%

3Y Avg-626.79%

Latest-899.04%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	4.84M	2.38M	6.7M	21.82M	26.27M	5.21M	3.74M	8.04M	14.54M	11.28M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	842K	997K	3.62M	4.12M	3.07M	2.35M	2.48M	5.34M	4.18M	4.64M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	4M	1.38M	7.8M	17.7M	23.19M	2.87M	1.25M	2.7M	10.36M	6.64M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	-99K	175K	0	0	0	0	0	0
Operating Income+	-4.84M	-2.38M	-11.42M	-21.82M	-26.27M	-5.21M	-3.74M	-8.04M	-14.54M	-11.28M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.51%	-3.8%	-0.91%	-0.2%	0.8%	0.28%	-1.15%	-0.81%	0.22%
EBITDA+	440K	0	0	0	-25.91M	-5.15M	0	-2.44M	0	-11.7M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1%	-	-	-	0.8%	1%	-	1%	-
D&A (Non-Cash Add-back)	5.28M	2.38M	11.42M	21.82M	0	0	3.74M	0	14.54M	0
EBIT	-4.84M	-2.56M	-11.88M	-21.55M	-25.91M	-5.15M	-3.73M	-2.44M	-10.49M	-11.7M
Net Interest Income+	-418K	0	-287K	0	357K	62K	7K	-1.14M	126K	176K
Interest Income	0	0	88K	93K	357K	62K	7K	20K	126K	176K
Interest Expense	417.82K	612K	375K	0	0	0	0	1.16M	0	0
Other Income/Expense	-383K	-800K	-837K	268K	357K	62K	7K	4.44M	4.05M	-413K
Pretax Income+	-5.23M	-3.18M	-12.26M	-21.55M	-25.91M	-5.15M	-3.73M	-3.6M	-10.49M	-11.7M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	-268K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	0.99%	0.99%	1%
Net Income+	-5.23M	-3.18M	-12.26M	-21.55M	-25.91M	-5.15M	-3.73M	-3.55M	-10.38M	-11.65M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.39%	-2.86%	-0.76%	-0.2%	0.8%	0.28%	0.05%	-1.92%	-0.12%
Net Income (Continuing)	-5.23M	-3.18M	-12.26M	-21.55M	-25.91M	-5.15M	-3.73M	-3.6M	-10.49M	-11.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	-639K	-928K	-941K
EPS (Diluted)+	-9.40	-5.39	-27.71	-31.17	-24.38	-4.65	-3.29	-121.91	-73.48	-0.90
EPS Growth %	-	0.43%	-4.14%	-0.12%	0.22%	0.81%	0.29%	-36.05%	0.4%	0.99%
EPS (Basic)	-9.40	-5.39	-27.71	-31.17	-24.38	-4.65	-3.29	-121.91	-73.60	-0.90
Diluted Shares Outstanding	556.1K	589.43K	442.33K	682.61K	1.05M	1.1M	1.13M	29.14K	141.22K	12.95M
Basic Shares Outstanding	556.1K	589.43K	442.33K	682.61K	1.05M	1.1M	1.13M	29.14K	141K	12.95M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14K	197K	22.17M	4.53M	8.91M	3.25M	3.96M	6.84M	1.85M	2.67M
Cash & Short-Term Investments	14K	197K	21.78M	2.67M	8.74M	3.13M	3.76M	6.71M	1.78M	2.59M
Cash Only	14K	197K	11.78M	2.67M	8.74M	3.13M	3.76M	6.71M	1.78M	2.59M
Short-Term Investments	0	0	10M	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	90K	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	1.7M	0	0	0	0	0	78K
Total Non-Current Assets+	0	0	0	1.85M	170K	113K	0	0	67K	0
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	1.85M	170K	113K	0	0	67K	0
Total Assets+	14K	197K	22.17M	4.53M	8.91M	3.25M	3.96M	6.84M	1.85M	2.67M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	13.07%	111.54%	-0.8%	0.97%	-0.64%	0.22%	0.73%	-0.73%	0.44%
Total Current Liabilities+	2.45M	6.42M	2.79M	5.16M	2.12M	886K	509K	3.58M	1.2M	816K
Accounts Payable	491K	334K	1.54M	3.09M	354K	172K	304K	150K	401K	155K
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	1.17M	3.85M	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	114K	1.66M	0	0	1M	0	24K	2.61M	784K	34K
Current Ratio	0.01x	0.03x	7.95x	0.88x	4.22x	3.66x	7.78x	1.91x	1.55x	3.27x
Quick Ratio	0.01x	0.03x	7.95x	0.88x	4.22x	3.66x	7.78x	1.91x	1.55x	3.27x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.7M	2.03M	0	0	0	0	0	0	0	0
Long-Term Debt	2.7M	2.03M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	5.15M	8.45M	2.79M	5.16M	2.12M	886K	509K	3.58M	1.2M	816K
Total Debt+	3.87M	5.87M	0	0	0	0	0	0	0	0
Net Debt	3.85M	5.68M	-11.78M	-2.67M	-8.74M	-3.13M	-3.76M	-6.71M	-1.78M	-2.59M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	8.79x	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	8.76x	-	-	-	-	-	-	-	-	-
Interest Coverage	-11.59x	-3.88x	-30.46x	-	-	-	-	-6.93x	-	-
Total Equity+	-5.13M	-8.25M	19.38M	-631K	6.8M	2.36M	3.45M	3.27M	654K	1.86M
Equity Growth %	-	-0.61%	3.35%	-1.03%	11.78%	-0.65%	0.46%	-0.05%	-0.8%	1.84%
Book Value per Share	-9.23	-13.99	43.81	-0.92	6.49	2.14	3.05	112.10	4.63	0.14
Total Shareholders' Equity	-5.13M	-8.25M	19.38M	-631K	6.8M	2.36M	3.45M	3.9M	1.58M	2.8M
Common Stock	1K	1K	1K	1K	2K	2K	0	0	3K	0
Retained Earnings	-5.23M	-8.4M	-20.66M	-42.21M	-68.12M	-73.27M	-77M	-80.55M	-90.93M	-102.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	40K	49K	1.1M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	-639K	-928K	-941K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-895K	-1.63M	-6.8M	-18.22M	-26.26M	-4.61M	-3.75M	-7.6M	-9.45M	-9.03M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.82%	-3.17%	-1.68%	-0.44%	0.82%	0.19%	-1.03%	-0.24%	0.04%
Net Income	-5.23M	-3.18M	-12.26M	-21.55M	-25.91M	-5.15M	-3.73M	-3.6M	-10.38M	-11.7M
Depreciation & Amortization	0	0	174K	0	0	0	0	0	0	0
Stock-Based Compensation	56	28K	604K	1.54M	1.84M	710K	442K	649K	906K	1.24M
Deferred Taxes	0	0	277K	0	0	0	0	0	0	0
Other Non-Cash Items	3.16M	435K	2.32M	412K	61K	0	0	-5.05M	310K	1.25M
Working Capital Changes	1.17M	1.08M	2.08M	1.79M	-2.25M	-172K	-461K	408K	-290K	179K
Change in Receivables	0	0	0	0	0	0	-90K	90K	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	15K	2.23M	1.13M	-3.23M	-229K	0	0	-360K	0
Cash from Investing+	-3M	0	-10M	10M	0	-1M	0	0	-3M	0
Capital Expenditures	-3M	0	0	0	0	-1M	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-3.27K	0	-10K	-10M	0	0	0	0	-3M	0
Cash from Financing+	3.91M	1.81M	28.39M	-895K	32.33M	0	4.38M	10.54M	7.53M	9.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-58K	-6.56M	-895K	-2.67M	0	-663K	148K	1K	8.21M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.9M	-1.63M	-6.8M	-18.22M	-26.26M	-5.61M	-3.75M	-7.6M	-12.45M	-9.03M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.58%	-3.17%	-1.68%	-0.44%	0.79%	0.33%	-1.03%	-0.64%	0.28%
FCF per Share	-7.00	-2.77	-15.38	-26.69	-25.06	-5.10	-3.31	-260.72	-88.17	-0.70
FCF Conversion (FCF/Net Income)	0.17x	0.51x	0.55x	0.85x	1.01x	0.90x	1.01x	2.14x	0.91x	0.77x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-220.23%	-229.86%	-839.94%	-112.48%	-128.43%	-105.76%	-529.44%	-928.45%
Return on Invested Capital (ROIC)	-	-	-340.79%	-761.73%	-	-	-	-	-	-
Interest Coverage	-11.59x	-3.88x	-30.46x	-	-	-	-	-6.93x	-	-
FCF Conversion	0.17x	0.51x	0.55x	0.85x	1.01x	0.90x	1.01x	2.14x	0.91x	0.77x

Frequently Asked Questions

Growth & Financials

Avenue Therapeutics, Inc. (ATXI) reported $1.4M in revenue for fiscal year 2024.

Avenue Therapeutics, Inc. (ATXI) grew revenue by 0.0% over the past year. Growth has been modest.

Avenue Therapeutics, Inc. (ATXI) reported a net loss of $3.7M for fiscal year 2024.

Dividend & Returns

Avenue Therapeutics, Inc. (ATXI) has a return on equity (ROE) of -928.4%. Negative ROE indicates the company is unprofitable.

Avenue Therapeutics, Inc. (ATXI) had negative free cash flow of $1.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Avenue Therapeutics, Inc. (ATXI) 10-Year Financial Performance & Capital Metrics

ATXI • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $0
EBITDA -$12M
Net Income -$12M -12.3%
EPS (Diluted) -0.90 +98.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -928.45% -75.4%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 87 (top 13%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM123.81%

ROCE

10Y Avg-422.59%

5Y Avg-424.57%

3Y Avg-626.79%

Latest-899.04%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	4.84M	2.38M	6.7M	21.82M	26.27M	5.21M	3.74M	8.04M	14.54M	11.28M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	842K	997K	3.62M	4.12M	3.07M	2.35M	2.48M	5.34M	4.18M	4.64M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	4M	1.38M	7.8M	17.7M	23.19M	2.87M	1.25M	2.7M	10.36M	6.64M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	-99K	175K	0	0	0	0	0	0
Operating Income+	-4.84M	-2.38M	-11.42M	-21.82M	-26.27M	-5.21M	-3.74M	-8.04M	-14.54M	-11.28M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.51%	-3.8%	-0.91%	-0.2%	0.8%	0.28%	-1.15%	-0.81%	0.22%
EBITDA+	440K	0	0	0	-25.91M	-5.15M	0	-2.44M	0	-11.7M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1%	-	-	-	0.8%	1%	-	1%	-
D&A (Non-Cash Add-back)	5.28M	2.38M	11.42M	21.82M	0	0	3.74M	0	14.54M	0
EBIT	-4.84M	-2.56M	-11.88M	-21.55M	-25.91M	-5.15M	-3.73M	-2.44M	-10.49M	-11.7M
Net Interest Income+	-418K	0	-287K	0	357K	62K	7K	-1.14M	126K	176K
Interest Income	0	0	88K	93K	357K	62K	7K	20K	126K	176K
Interest Expense	417.82K	612K	375K	0	0	0	0	1.16M	0	0
Other Income/Expense	-383K	-800K	-837K	268K	357K	62K	7K	4.44M	4.05M	-413K
Pretax Income+	-5.23M	-3.18M	-12.26M	-21.55M	-25.91M	-5.15M	-3.73M	-3.6M	-10.49M	-11.7M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	-268K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	0.99%	0.99%	1%
Net Income+	-5.23M	-3.18M	-12.26M	-21.55M	-25.91M	-5.15M	-3.73M	-3.55M	-10.38M	-11.65M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.39%	-2.86%	-0.76%	-0.2%	0.8%	0.28%	0.05%	-1.92%	-0.12%
Net Income (Continuing)	-5.23M	-3.18M	-12.26M	-21.55M	-25.91M	-5.15M	-3.73M	-3.6M	-10.49M	-11.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	-639K	-928K	-941K
EPS (Diluted)+	-9.40	-5.39	-27.71	-31.17	-24.38	-4.65	-3.29	-121.91	-73.48	-0.90
EPS Growth %	-	0.43%	-4.14%	-0.12%	0.22%	0.81%	0.29%	-36.05%	0.4%	0.99%
EPS (Basic)	-9.40	-5.39	-27.71	-31.17	-24.38	-4.65	-3.29	-121.91	-73.60	-0.90
Diluted Shares Outstanding	556.1K	589.43K	442.33K	682.61K	1.05M	1.1M	1.13M	29.14K	141.22K	12.95M
Basic Shares Outstanding	556.1K	589.43K	442.33K	682.61K	1.05M	1.1M	1.13M	29.14K	141K	12.95M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14K	197K	22.17M	4.53M	8.91M	3.25M	3.96M	6.84M	1.85M	2.67M
Cash & Short-Term Investments	14K	197K	21.78M	2.67M	8.74M	3.13M	3.76M	6.71M	1.78M	2.59M
Cash Only	14K	197K	11.78M	2.67M	8.74M	3.13M	3.76M	6.71M	1.78M	2.59M
Short-Term Investments	0	0	10M	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	90K	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	1.7M	0	0	0	0	0	78K
Total Non-Current Assets+	0	0	0	1.85M	170K	113K	0	0	67K	0
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	1.85M	170K	113K	0	0	67K	0
Total Assets+	14K	197K	22.17M	4.53M	8.91M	3.25M	3.96M	6.84M	1.85M	2.67M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	13.07%	111.54%	-0.8%	0.97%	-0.64%	0.22%	0.73%	-0.73%	0.44%
Total Current Liabilities+	2.45M	6.42M	2.79M	5.16M	2.12M	886K	509K	3.58M	1.2M	816K
Accounts Payable	491K	334K	1.54M	3.09M	354K	172K	304K	150K	401K	155K
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	1.17M	3.85M	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	114K	1.66M	0	0	1M	0	24K	2.61M	784K	34K
Current Ratio	0.01x	0.03x	7.95x	0.88x	4.22x	3.66x	7.78x	1.91x	1.55x	3.27x
Quick Ratio	0.01x	0.03x	7.95x	0.88x	4.22x	3.66x	7.78x	1.91x	1.55x	3.27x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.7M	2.03M	0	0	0	0	0	0	0	0
Long-Term Debt	2.7M	2.03M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	5.15M	8.45M	2.79M	5.16M	2.12M	886K	509K	3.58M	1.2M	816K
Total Debt+	3.87M	5.87M	0	0	0	0	0	0	0	0
Net Debt	3.85M	5.68M	-11.78M	-2.67M	-8.74M	-3.13M	-3.76M	-6.71M	-1.78M	-2.59M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	8.79x	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	8.76x	-	-	-	-	-	-	-	-	-
Interest Coverage	-11.59x	-3.88x	-30.46x	-	-	-	-	-6.93x	-	-
Total Equity+	-5.13M	-8.25M	19.38M	-631K	6.8M	2.36M	3.45M	3.27M	654K	1.86M
Equity Growth %	-	-0.61%	3.35%	-1.03%	11.78%	-0.65%	0.46%	-0.05%	-0.8%	1.84%
Book Value per Share	-9.23	-13.99	43.81	-0.92	6.49	2.14	3.05	112.10	4.63	0.14
Total Shareholders' Equity	-5.13M	-8.25M	19.38M	-631K	6.8M	2.36M	3.45M	3.9M	1.58M	2.8M
Common Stock	1K	1K	1K	1K	2K	2K	0	0	3K	0
Retained Earnings	-5.23M	-8.4M	-20.66M	-42.21M	-68.12M	-73.27M	-77M	-80.55M	-90.93M	-102.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	40K	49K	1.1M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	-639K	-928K	-941K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-895K	-1.63M	-6.8M	-18.22M	-26.26M	-4.61M	-3.75M	-7.6M	-9.45M	-9.03M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.82%	-3.17%	-1.68%	-0.44%	0.82%	0.19%	-1.03%	-0.24%	0.04%
Net Income	-5.23M	-3.18M	-12.26M	-21.55M	-25.91M	-5.15M	-3.73M	-3.6M	-10.38M	-11.7M
Depreciation & Amortization	0	0	174K	0	0	0	0	0	0	0
Stock-Based Compensation	56	28K	604K	1.54M	1.84M	710K	442K	649K	906K	1.24M
Deferred Taxes	0	0	277K	0	0	0	0	0	0	0
Other Non-Cash Items	3.16M	435K	2.32M	412K	61K	0	0	-5.05M	310K	1.25M
Working Capital Changes	1.17M	1.08M	2.08M	1.79M	-2.25M	-172K	-461K	408K	-290K	179K
Change in Receivables	0	0	0	0	0	0	-90K	90K	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	15K	2.23M	1.13M	-3.23M	-229K	0	0	-360K	0
Cash from Investing+	-3M	0	-10M	10M	0	-1M	0	0	-3M	0
Capital Expenditures	-3M	0	0	0	0	-1M	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-3.27K	0	-10K	-10M	0	0	0	0	-3M	0
Cash from Financing+	3.91M	1.81M	28.39M	-895K	32.33M	0	4.38M	10.54M	7.53M	9.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-58K	-6.56M	-895K	-2.67M	0	-663K	148K	1K	8.21M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.9M	-1.63M	-6.8M	-18.22M	-26.26M	-5.61M	-3.75M	-7.6M	-12.45M	-9.03M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.58%	-3.17%	-1.68%	-0.44%	0.79%	0.33%	-1.03%	-0.64%	0.28%
FCF per Share	-7.00	-2.77	-15.38	-26.69	-25.06	-5.10	-3.31	-260.72	-88.17	-0.70
FCF Conversion (FCF/Net Income)	0.17x	0.51x	0.55x	0.85x	1.01x	0.90x	1.01x	2.14x	0.91x	0.77x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-220.23%	-229.86%	-839.94%	-112.48%	-128.43%	-105.76%	-529.44%	-928.45%
Return on Invested Capital (ROIC)	-	-	-340.79%	-761.73%	-	-	-	-	-	-
Interest Coverage	-11.59x	-3.88x	-30.46x	-	-	-	-	-6.93x	-	-
FCF Conversion	0.17x	0.51x	0.55x	0.85x	1.01x	0.90x	1.01x	2.14x	0.91x	0.77x

Frequently Asked Questions

Growth & Financials

Avenue Therapeutics, Inc. (ATXI) reported $1.4M in revenue for fiscal year 2024.

Avenue Therapeutics, Inc. (ATXI) grew revenue by 0.0% over the past year. Growth has been modest.

Avenue Therapeutics, Inc. (ATXI) reported a net loss of $3.7M for fiscal year 2024.

Dividend & Returns

Avenue Therapeutics, Inc. (ATXI) has a return on equity (ROE) of -928.4%. Negative ROE indicates the company is unprofitable.

Avenue Therapeutics, Inc. (ATXI) had negative free cash flow of $1.7M in fiscal year 2024, likely due to heavy capital investments.